On a Tuesday morning in late September 2026, Oura Health Oy priced its initial public offering at the ceiling of its marketed range โ $44 per share โ minting a $14.1 billion valuation for a company whose primary product is a titanium ring that tracks your heartbeat while you sleep. The financial press responded with its customary choreography: "wearable unicorn," "4x oversubscribed," "the future of preventative health." Jim Cramer said something predictable on CNBC. The stock popped 18% before settling into the quiet that always precedes quarterly earnings reports, when the story is still intact and no one has yet asked the hard questions.
I watched the coverage from my apartment in Manila, a city where the line between "cutting-edge fintech" and "predatory lending" is often drawn by whoever has the loudest marketing budget. I have been writing about decentralization and data sovereignty for nearly a decade โ first as a nineteen-year-old finance student frustrated by the opacity of traditional markets, later as the founder of a Web3 community for women and marginalized creators, and now as someone who has watched three crypto cycles hollow out and rebuild the same promises. From this vantage point, Oura's IPO is not a triumph of health technology. It is a Rorschach test for the data economy. And the image it yields is deeply uncomfortable.
Here is the contradiction at the heart of the offering: Oura sold itself to public markets as a software company โ a subscription business with recurring revenue, high margins, and the kind of "data moat" that venture capitalists love to price at 20x forward sales. But 80% of its revenue comes from selling physical rings. The subscription โ $240.5 million over nine months โ is a beautiful story wrapped around a hardware business. And the "data moat" is built on the most intimate biometrics a human being can generate: your sleep cycles, your heart rate variability, your body temperature, your menstrual cycle, the architecture of your recovery from stress and exertion. Data that, under the European Union's General Data Protection Regulation, is classified as "special category" โ the most protected tier of personal information, requiring explicit consent and stringent safeguards. Data that Oura does not really let you own. It lets you access it, for a fee. And when you stop paying, the ring becomes a quiet piece of metal on your nightstand.
This is the tension I want to explore. Not whether Oura is a good company โ by traditional metrics, it appears to be a real one, with revenue up 74% year-over-year and a net income of $60.8 million. The question is what its IPO reveals about the trajectory of the data economy, and why the crypto industry โ which has spent a decade promising an alternative โ has so little to show for it.
Oura was founded in 2013 in Oulu, Finland, a city better known for its proximity to the Arctic Circle than for consumer electronics. The company's first ring shipped in 2015, and for several years it occupied a strange niche: a wellness product marketed to biohackers, quantified-self enthusiasts, and professional athletes who wanted to track recovery without strapping a screen to their wrist. The product was elegant, the battery life was exceptional, and the health insights โ particularly around sleep and recovery โ were genuinely differentiated. By the early 2020s, Oura had become the de facto standard for sleep tracking, partnered with the NBA and other professional sports leagues, and built a devoted community of users who treated their "readiness score" with the same seriousness that day traders reserve for candlestick patterns.
The subscription model arrived in 2018, ostensibly to fund ongoing software development and algorithmic improvements. Users paid $5.99 per month for insights that were, in earlier product iterations, largely included in the hardware purchase. The move generated significant backlash โ a pattern that would repeat itself across the consumer IoT landscape โ but it also worked. By 2026, Oura had roughly 5 million members, a figure that had doubled over the preceding year, and subscription revenue had become the centerpiece of its growth narrative.
Now consider the market context. In 2026, the IPO landscape is a desert dotted with a handful of oases. Kraken's parent company, Payward, delayed its own listing to 2027. Holtec Nuclear and Bamboo Insurance shelved their offerings. The only ten-billion-dollar-plus IPO before Oura's was Jersey Mike's, a sandwich chain, in July. This scarcity matters enormously for how Oura's offering was priced and received. When supply is thin, buyers bid up whatever looks clean, branded, and defensible. Oura arrived at exactly the right moment โ a well-marketed health brand with a growth story, entering a market starved for new issues. The 4x oversubscription is less a reflection of fundamental enthusiasm for smart rings than a symptom of capital chasing a scarcity premium. And the former New York Fed president, Bill Dudley, had spent the summer warning that equity markets were in bubble territory โ a warning that, if taken seriously, makes the enthusiasm for Oura's valuation look less like conviction and more like window-shopping.
The capital structure of the offering makes this even clearer. Of the $2.2 billion raised, only 27% โ roughly $594 million โ represented new capital for the company. The remaining 73% went to selling shareholders: early employees, venture investors, and founders converting illiquid equity into cash. This is not necessarily nefarious; it is standard practice in venture-backed offerings. But it changes the character of the event. An IPO in which nearly three-quarters of the proceeds go to insiders is not primarily a growth financing. It is a liquidity event โ a mechanism for the earliest stakeholders to realize returns, dressed up in the language of public-market validation.
For anyone who has spent time in crypto, this structure should feel hauntingly familiar. It is, functionally, a token generation event in which 73% of the supply is unlocked at listing and distributed to the founding team and early backers, with retail buyers providing the exit liquidity. The crypto community has a name for this: a "VC dump," or more politely, "tokens with poor tokenomics." The difference is that in crypto, such launches are met with public criticism, on-chain forensics, and community backlash. In traditional finance, they are celebrated as successful offerings. The asymmetry is instructive. It suggests that the transparency crypto offers โ imperfect though it is โ has not yet been translated into the institutional market, and that the cultural critique that animates much of Web3 has not penetrated the mainstream financial press.
I remember sitting in a university lecture hall in 2017, listening to a professor explain the mechanics of an IPO. The process seemed clinical: a company needed capital, it sold shares, the market priced them. What the lecture did not explain was the social construction of value โ the way a narrative about growth could inflate a multiple far beyond what the underlying cash flows justified. It took the ICO boom, and then the DeFi summer, and then the brutal bear market of 2022, for me to understand that valuation is a story. And the story Oura is telling is one that the crypto industry should be paying very close attention to, because it is the story of the centralized data economy at its most seductive and most dangerous.
Now let me get to the substance. I want to examine the four pillars of Oura's public-market story โ the data moat, the subscription economics, the competitive position, and the platform dynamics โ and show why each one, examined closely, points toward the same uncomfortable conclusion: that the company is being priced for a future it has not yet earned, and that the gap is filled in by a narrative about data ownership that runs directly against the principles many of us in this industry hold.
The Data Body and the Privacy Paradox
Let's start with the data, because that is where the story is most revealing.
Oura's value proposition is simple: the ring senses, the cloud interprets, the subscription delivers insight. Your sleep stages, your resting heart rate, your heart rate variability, your respiratory rate, your body temperature deviations, your menstrual cycle phase, your readiness score โ these are the outputs of an algorithmic pipeline trained on the biometric data of millions of users. The data is the moat, or at least the story of a moat. But it is also the company's most significant regulatory exposure.
Under GDPR, biometric data used to uniquely identify a person, and health data more broadly, are classified as "special category" data. Processing such data requires a lawful basis, and for health data, explicit consent is generally required. Cross-border transfers of this data โ from a user in Manila to a server in the United States, for instance โ must satisfy the stringent requirements established by the Schrems II decision and its successor frameworks. This is not a theoretical concern. Meta was fined โฌ1.2 billion in 2023 for transferring European user data to the United States. Health data is held to an even higher standard.
Oura has not been publicly accused of any data-protection violation, and I want to be careful not to imply otherwise. But the regulatory architecture around its core asset creates a ceiling on how aggressively it can monetize. The "data network effect" โ the idea that more users make the algorithms smarter โ is real, but the value created is constrained by what the company can legally do with the underlying data. Selling it to insurers, employers, or advertisers is fraught with consent issues. Even internal use is subject to auditing and purpose limitation. And in the United States, the patchwork of state-level health data laws โ Washington's My Health My Data Act, Nevada's equivalent, and whatever emerges next โ creates a compliance burden that scales with the business.
I have seen this dynamic from the inside. When I helped build Decentralized Hearts, our community for women and marginalized creators in the NFT space, we wanted to build tools that would let our members control their own data โ portfolio histories, identity credentials, creative provenance โ without relying on third-party platforms. The technology existed in fragments: decentralized identifiers, verifiable credentials, encrypted storage. What did not exist was a cohesive user experience. Onboarding a user who had never installed a wallet required walking them through seed phrase management, gas fees, and the labyrinth of wallet connectivity. We lost more people to frustration than we ever lost to distrust of decentralization. That experience taught me something important: the centralized model persists not because it is more aligned with user interests, but because it is easier. Ease of use is a form of lock-in.
Oura's data custody model reflects the same dynamic. The ring is easy to use. The app is polished. The insights arrive without any friction beyond the monthly fee. But the ease comes at the cost of ownership. Users cannot extract their raw biometric data and take it to a competing platform โ not legally, not practically. There is no portable health data standard that would let a user move from Oura to Whoop and preserve their history. The data is a silo, and the silo is the business.
In a decentralized model, the user would hold the keys to their biometric data, grant access to algorithmic processors through verifiable credentials, and revoke that access at will. Protocols being built on decentralized identity standards โ self-sovereign identity, zero-knowledge proofs of health state, encrypted data vaults โ aim to make data portable and user-controlled. The technology is immature and the user experience is poor. I know this from professional experience. But the gap between what decentralized systems promise and what they deliver is a gap in execution, not in the underlying architecture. Oura's IPO is a reminder of how much value is concentrated in the centralized model โ and how much of that value is extracted from data that, in a just world, would belong to the people who generate it.
The Subscription Illusion
Now the subscription. This is the heart of the "software company" narrative, and it deserves scrutiny.
The numbers as reported: $240.5 million in subscription revenue over nine months, against $974 million in hardware revenue. That puts subscription at roughly 20% of total revenue. The company's growth in members โ doubling to 5 million โ is impressive in absolute terms. But the ratio tells the real story. Apple, the archetype of a software-services business, derives roughly 25% of revenue from services but at vastly higher margins and without a hardware dependency. Salesforce, the archetype of a pure software company, derives essentially all revenue from subscriptions. Oura derives one-fifth, and it is priced as though the line will cross 50% and eventually 80%. That is the bet public-market investors are being asked to make. On what basis should they make it?
Here is where the arithmetic becomes interesting. If subscription revenue is $240.5 million over nine months, and the company has 5 million members at the end of that period โ but the membership doubled during the period, meaning the average member count was far lower โ then the implied average revenue per user (ARPU) is well below the $5.99 monthly sticker price. Let's do the rough math. Nine months of $5.99 is $53.91 per member. If the average member count over the period was, say, 3 million โ a generous midpoint, since the doubling happened over a year โ the implied annualized subscription revenue would be about $161.7 million, or roughly $4.50 per member per month. That gap between sticker price and realized ARPU reflects free trials, annual plans with suspended charges, promotional discounts, and bundle deals โ the standard toolkit of consumer subscription growth. It is not a scandal. It is also not the pristine recurring revenue that the "software multiple" framing implies.
I have run the numbers on subscription businesses before, in my days as a junior analyst at a fintech firm in Manila. The gap between headline pricing and realized ARPU was one of the first things I learned to look for. It is a tell. When a company promotes its subscriber count without disclosing churn, and its ARPU without disclosing promotional dilution, it is curating the story. Oura is not doing anything unusual โ every consumer subscription company does this โ but the curation matters when the valuation depends on the quality of the recurring revenue.
Then there is the platform tax. If Oura's subscription revenue is processed through the App Store โ which is the default path for iOS-sold subscriptions โ Apple takes a 15% to 30% cut. The exact split depends on whether the user has been subscribed for more than a year (15% under the Small Business Program or for long-term subscriptions) or less (30% standard). Let's assume a blended 20%. On $240.5 million, that is roughly $48 million in platform fees โ a figure that appears nowhere in the headline revenue but materially affects gross margin. And it is subject to the shifting rules of the Digital Markets Act in Europe and the ongoing antitrust cases in the United States, meaning the company cannot fully control its own cost of revenue.
This is not a unique burden โ every app-based subscription business faces it โ but it is a concentrated dependency that the "software company" narrative tends to obscure. In crypto, the equivalent would be a protocol that routes all its fee revenue through a single centralized exchange, paying a 20% toll and subject to that exchange's unilateral rule changes. The community would call that a governance risk of the highest order. In traditional finance, it is a footnote.
The Competitive Window
Oura's position in the smart ring category is genuinely strong. It got there first, built a premium brand, and cultivated the kind of emotional resonance with its users that few consumer devices achieve. But the moat is narrower than it appears, and it is narrowing.
Samsung shipped its Galaxy Ring in 2024. Whoop โ a company valued at $10.1 billion in its own right โ dominates the wrist-based recovery market and has been steadily encroaching on Oura's territory. But the more existential threats are Apple and Google, both of which have the hardware supply chains, distribution channels, and software ecosystems to enter the ring category at scale if they choose to. Apple's health ambitions are well-documented; the Apple Watch already covers much of the functionality Oura offers, and adding a ring form factor would be a manufacturing and design exercise, not a technical breakthrough. Google owns Fitbit and has been integrating health data across its ecosystem.
The reason Oura has been able to sustain premium pricing and a premium valuation is that these giants have not yet prioritized the ring category. That is not a durable competitive advantage. It is a timing gift โ the kind of cushion that exists only until it doesn't. And the IPO itself may accelerate the end of that cushion, because public-market scrutiny and capital availability signal to competitors that the category is worth entering.
The crypto parallel here is bracing. There is a recurring fantasy in Web3 that the incumbents โ the centralized exchanges, the banks, the tech platforms โ will not enter the space, or that when they do, they will do so half-heartedly. That fantasy has been disproven repeatedly. Coinbase now competes directly with DeFi protocols; BlackRock's Bitcoin ETF absorbed demand that once flowed to on-chain products; and platforms like Robinhood have integrated crypto trading into user experiences that legacy Web3 products cannot match. The lesson is consistent: incumbents enter when the market is large enough and the customer acquisition cost is low enough. Oura's public listing confirms that the health-wearable market is now both.
I have felt this dynamic personally. When my community launched in 2021, we were early to the idea of using NFTs as a community-building tool for marginalized creators. By 2023, every major platform had a version of the same feature, and the competitive advantage we thought we had โ the cultural specificity, the community trust โ was not enough to offset the distribution advantages of incumbents. The lesson was not that decentralization is worthless. It was that decentralization is not itself a moat. The moat is the community, the trust, the shared values. And those are harder to maintain at scale than any technical advantage.
The Liquidity Event
Which brings me back to the structure of the offering. The 73% secondary share component is the most significant signal in the entire transaction, and it is the one most consistently overlooked.
When a company's early investors and employees sell the majority of their holdings at IPO, they are communicating something. They are not necessarily saying the company is doomed โ venture funds have fund lives to manage, employees have taxes to pay, and diversification is rational. But the disclosure that the founders and earliest backers are monetizing at this valuation, at a moment of peak market enthusiasm, rather than holding for the next leg of growth, is a data point that deserves more weight than the subscription-to-hardware ratio.
Consider it through the crypto lens again. When a project launches with a token distribution in which 73% of the allocated supply is unlocked and held by insiders, token analysts call it a "high float, low vesting" structure and warn of relentless selling pressure. When a company does the same through an IPO, it is called a successful exit. The mechanics are similar; the language is different. The liquidity premium that public markets are paying for Oura โ the 4x oversubscription, the top-of-range pricing โ is, in a real sense, the premium that buyers are paying to provide exit liquidity to earlier holders.
I do not mean to suggest that all IPOs with secondary components are pump-and-dumps. They are not. But the composition of this offering โ combined with a valuation that relies on a multiple mismatched to the revenue base โ creates a risk profile that the "health tech innovation" narrative obscures. The company's long-term success will be determined by whether it can convert hardware buyers into long-term subscribers, scale its B2B insurance and enterprise channels, and fend off Big Tech entry. The IPO itself tells us nothing about any of that. It tells us that early holders wanted out, and that public investors were willing to buy the story.
Let me now offer the counterargument I find most compelling, and explain why I ultimately reject it.
The bull case for Oura goes like this: the hard part of a health-data company is not selling the hardware; it is building the trust, the brand, and the algorithmic competence to interpret biometric data in a way that users find valuable enough to pay for. Oura has done that. The hardware is a loss leader โ a physical manifestation of the brand that creates switching costs, generates the data that trains the models, and locks users into an ecosystem. The subscription is where the margin lives, and it will grow as a share of revenue. The B2B channel โ insurance, corporate wellness, clinical research โ is underdeveloped but has substantial potential. And the data, if handled with proper consent and governance, can become a genuine competitive asset.
In this reading, the IPO is the beginning of a long transition from consumer hardware to health-services platform, and early stockholders selling into it is rational portfolio management, not a signal of doubt.
The argument is coherent. I do not find it convincing, for three reasons.
First, the transition it describes โ hardware to software โ is the hardest pivot in consumer technology. Companies rarely pull it off. Peloton tried and failed. Fitbit tried and was acquired. GoPro tried and shrank. The subscription attach rate Oura needs to justify its multiple is not just a matter of improving retention; it is a matter of reorienting the entire business model, which requires capabilities that are not evident in the current organization.
Second, the data moat is legally constrained in ways that the bull case underestimates. The most valuable applications of health data โ underwriting, risk assessment, targeted intervention โ run directly into privacy regulation and user distrust. The recent controversies over health data in the United States, including the legal battles over period-tracking data after the Dobbs decision, demonstrate that users are increasingly unwilling to accept silent monetization of their biometrics. Any attempt to monetize Oura's data beyond the subscription fee will face resistance, both regulatory and cultural.
Third, and most importantly, the bull case does not account for the valuation. Even if everything goes right โ subscription penetration doubles, B2B scales, Big Tech never enters โ the company would still be a hardware business with a growing services layer, deserving of a multiple somewhere between consumer electronics (10-15x earnings) and SaaS (30-40x revenue). The current IPO valuation prices it at the high end of the second range, implying that the transition has already happened. It has not. And when the market realizes that, the adjustment will be painful.
There is a deeper philosophical question here, one that goes beyond Oura and touches the heart of what we in Web3 are trying to build. The bull case assumes that centralized data custody is efficient โ that a single company can process, protect, and monetize personal data more effectively than the individual can. That assumption is increasingly questionable. The cost of data breaches, the regulatory burden of compliance, and the reputational risk of misuse all scale with the size of the data silo. A decentralized model distributes those costs across the network, where they belong. The technology is not ready. The incentives are not aligned. But the direction of travel is clear.
So where does this leave us? From the ashes of 2022, we planted seeds for 2030 โ that was the mantra I kept returning to during the bear market, when my own portfolio had drawn down by 85% and the temptation to abandon the industry was overwhelming. I wrote it as a reminder that the cycles are longer than the headlines, that the value being built during the quiet years is the foundation for whatever comes next.
Oura's IPO is a reminder of how much value still accrues to centralized data custodians, and how far the decentralized alternative remains from being competitive. But it is also a map of where the opportunity lies. The subscription economy is dependent on platform choke points and legal constraints. The data economy is dependent on user consent that is increasingly fragile. And the hardware economy is dependent on supply chains that are increasingly commoditized. Each of these dependencies is a weakness. Each weakness is an opening.
The question I keep returning to is not whether Oura will succeed as a public company. It might. The question is whether the model it represents โ intimate data extracted, processed, and monetized by a centralized entity, with the user granted access only for a fee โ is the model we want for the next decade of health technology. Because if it is, then the decentralized alternatives we have spent years building will remain a niche within a niche, admired but not adopted.
The ring is on the finger. The data has been collected. The question now is who owns the story it tells. And for the first time in years, I am not sure the answer favors us.